[{"data":1,"prerenderedAt":225},["ShallowReactive",2],{"drug-baricitinib":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":50,"contraindications":107,"warnings":108,"renal":116,"monitoring":117,"interactions":118,"review":119,"examples":122,"atc":138,"iran":140,"usApproval":160,"links":166,"populations":182},"baricitinib",1,{"fa":7,"en":8},"باریسیتینیب","Baricitinib","antineoplastic-immunomodulating",{"fa":11,"en":12},"مهارکننده JAK","JAK inhibitor",[14],{"name":15,"market":16},"Olumiant","US",[18,19,7],"olumiant","اولومیانت",[21,34,42],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"tab-1","tablet","oral","1 mg tablet",{"amount":5,"unit":27,"perUnit":23,"scored":28},"mg",false,[16],[31],{"source":32,"section":33},"fda-olumiant","3",{"id":35,"form":23,"route":24,"label":36,"concentration":37,"markets":39,"refs":40},"tab-2","2 mg tablet",{"amount":38,"unit":27,"perUnit":23,"scored":28},2,[16],[41],{"source":32,"section":33},{"id":43,"form":23,"route":24,"label":44,"concentration":45,"markets":47,"refs":48},"tab-4","4 mg tablet",{"amount":46,"unit":27,"perUnit":23,"scored":28},4,[16],[49],{"source":32,"section":33},[51,66,87],{"id":52,"disease":53,"label":54,"population":57,"type":61,"unit":27,"dose":62,"refs":63},"ra","rheumatoid-arthritis",{"fa":55,"en":56},"آرتریت روماتوئید — ۲ mg یک بار در روز","Rheumatoid arthritis — 2 mg once daily",{"minAge":58},{"value":59,"unit":60},18,"year","fixed",{"perDose":38,"dosesPerDay":5},[64],{"source":32,"section":65},"2.2",{"id":67,"disease":68,"label":69,"population":72,"type":61,"unit":27,"dose":74,"refs":75,"durationDays":78,"notes":80},"covid","covid-19",{"fa":70,"en":71},"کووید-۱۹ بستری — بزرگسال ۴ mg یک بار در روز تا ۱۴ روز","Hospitalised COVID-19 — adult 4 mg once daily up to 14 days",{"minAge":73},{"value":59,"unit":60},{"perDose":46,"dosesPerDay":5},[76],{"source":32,"section":77},"2.3",{"min":5,"max":79},14,[81],{"text":82,"refs":85},{"fa":83,"en":84},"۱۴ روز یا تا ترخیص، هر کدام زودتر.","14 days or until discharge, whichever comes first.",[86],{"source":32,"section":77},{"id":88,"disease":89,"label":90,"population":93,"type":61,"unit":27,"dose":96,"refs":97,"notes":100},"aa","alopecia",{"fa":91,"en":92},"آلوپسی آره‌آتای شدید (۱۲ سال به بالا) — ۲ mg، در صورت پاسخ ناکافی ۴ mg","Severe alopecia areata (≥12 y) — 2 mg, 4 mg if inadequate response",{"minAge":94},{"value":95,"unit":60},12,{"perDose":38,"perDoseMax":46,"dosesPerDay":5},[98],{"source":32,"section":99},"2.4",[101],{"text":102,"refs":105},{"fa":103,"en":104},"ریزش تقریباً کامل مو: شروع با ۴ mg قابل‌بررسی؛ پس از پاسخ به ۲ mg کاهش.","Nearly complete hair loss: consider starting with 4 mg; reduce to 2 mg once responding.",[106],{"source":32,"section":99},[],[109],{"text":110,"refs":113},{"fa":111,"en":112},"هشدار جعبه‌ای (مهارکننده JAK): عفونت جدی، مرگ، بدخیمی، حوادث قلبی‌عروقی بزرگ و ترومبوز. تست سل پیش از شروع.","Boxed warning (JAK inhibitors): serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. TB test before starting.",[114],{"source":32,"section":115},"Boxed Warning",[],[],[],{"status":120,"reviewer":121,"date":121},"unverified",null,[123,128,133],{"regimen":52,"formulation":35,"input":124,"expect":127},{"ageYears":125,"weightKg":126},50,70,{"perDose":38,"tabletsPerDoseRounded":5},{"regimen":67,"formulation":43,"input":129,"expect":132},{"ageYears":130,"weightKg":131},60,80,{"perDose":46,"tabletsPerDoseRounded":5},{"regimen":88,"formulation":35,"input":134,"expect":137},{"ageYears":135,"weightKg":136},30,65,{"perDose":38,"tabletsPerDoseRounded":5,"upperPerDose":46},[139],"L04AF02",{"status":141,"forms":142,"refs":155},"registered",[143,147,151],{"code":144,"en":145,"fa":146},"52844","BARICITINIB 2MG TAB","قرص باریسیتینیب ۲ میلی‌گرم",{"code":148,"en":149,"fa":150},"52845","BARICITINIB 4MG TAB","قرص باریسیتینیب ۴ میلی‌گرم",{"code":152,"en":153,"fa":154},"52937","BARICITINIB TABLET ORAL 1 mg","قرص باریسیتینیب ۱ میلی‌گرم",[156],{"source":157,"section":158,"url":159},"darooyab-generic","G-1716\u002FBaricitinib","https:\u002F\u002Fwww.darooyab.ir\u002FG-1716\u002FBaricitinib",{"kind":161,"refs":162,"id":165},"NDA",[163],{"source":32,"section":164},"SPL approval \u002F marketing category","NDA207924",[167,170,174,177,180],{"kind":168,"url":169,"label":165},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=207924",{"kind":171,"url":172,"label":173},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf","FDA Olumiant",{"kind":175,"url":176,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa618033.html",{"kind":178,"url":179,"label":139},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L04AF02",{"kind":181,"url":159,"label":8},"darooyab",{"pregnancy":183,"lactation":192,"pediatric":200,"geriatric":209,"reproductive":217},{"level":184,"text":185,"quote":188,"refs":189},"avoid",{"fa":186,"en":187},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on the findings from animal reproduction studies, OLUMIANT may cause fetal harm during pregnancy.",[190],{"source":32,"section":191},"8.1",{"level":184,"text":193,"quote":196,"refs":197},{"fa":194,"en":195},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in nursing infants advise women not to breastfeed during treatment with OLUMIANT and for 4 days after the last dose (approximately 5 to 6 elimination half-lives).",[198],{"source":32,"section":199},"8.2",{"level":201,"text":202,"quote":205,"refs":206},"caution",{"fa":203,"en":204},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of OLUMIANT for the treatment of severe alopecia areata have been established in pediatric patients 12 years of age and older.",[207],{"source":32,"section":208},"8.4",{"level":201,"text":210,"quote":213,"refs":214},{"fa":211,"en":212},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because geriatric patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration ( 2.6 )] .",[215],{"source":32,"section":216},"8.5",{"level":201,"text":218,"quote":221,"refs":222},{"fa":219,"en":220},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Based on animal studies, OLUMIANT may cause fetal harm when administered during pregnancy [see Use in Specific Populations ( 8.1 )] .",[223],{"source":32,"section":224},"8.3",1792156163936]